Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and received approval for bone-strengthening drug Prolia/Xgeva in 2010. Amgen's acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering) and Aimovig (migraine).
| Website: | www.amgen.com |
| Email: | investor.relations@amgen.com |
| Main Phone: | +1 805 447-1000 |
| Address: | One Amgen Center Drive |
| Address 2: | Suite 2650 |
| State: | CA |
| City / Town: | Thousand Oaks |
| Country: | US |
| Postal Code: | 91320-1799 |
| Exchange: | NGS |
| CEO: | Robert A. Bradway |
| Employees: | 23400 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
The new names join the index as of August 31. Exxon Mobil, Pfizer and Raytheon will depart.
With a coronavirus vaccine still months off, companies are rushing to test what may be the next best thing: drugs that deliver antibodies to fight the virus right away, without having to train the immune system to make them.
Higher sales of newer drugs, like recently-added psoriasis treatment Otezla, offset declining sales of older medicines. Adjusted earnings rose 4% to $2.52 billion, or $4.25 per share, vs estimates of $3.84.
The company reported an 11% increase in revenue and 17% increase in adjusted profit, while maintaining its full-year forecast.
Deal was more than doubled in size, priced at $17 and never traded below $28.
Let's take a deep dive into sectors, the Fed and trade wars.
Omecamtiv mecarbil, a cardiac myosin activator, is being studied in heart failure with reduced ejection fraction (HFrEF)
Developing T cell engagers targeting prostate cancer, ovarian cancer, multiple myeloma and small cell lung cancer (Image: Harpoon Therapeutics)
The proposed deal for this biotechnology unicorn would be the largest US IPO in the industry (Image: Moderna)
The noise trader influence is only growing, as the rise of self-directed traders and the relentless noise of the financial press mean the noise to signal ratio is worse than ever.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and received approval for bone-strengthening drug Prolia/Xgeva in 2010. Amgen's acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering) and Aimovig (migraine).
| Website: | www.amgen.com |
| Email: | investor.relations@amgen.com |
| Main Phone: | +1 805 447-1000 |
| Address: | One Amgen Center Drive |
| Address 2: | Suite 2650 |
| State: | CA |
| City / Town: | Thousand Oaks |
| Country: | US |
| Postal Code: | 91320-1799 |
| Exchange: | NGS |
| CEO: | Robert A. Bradway |
| Employees: | 23400 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
The new names join the index as of August 31. Exxon Mobil, Pfizer and Raytheon will depart.
With a coronavirus vaccine still months off, companies are rushing to test what may be the next best thing: drugs that deliver antibodies to fight the virus right away, without having to train the immune system to make them.
Higher sales of newer drugs, like recently-added psoriasis treatment Otezla, offset declining sales of older medicines. Adjusted earnings rose 4% to $2.52 billion, or $4.25 per share, vs estimates of $3.84.
The company reported an 11% increase in revenue and 17% increase in adjusted profit, while maintaining its full-year forecast.
Deal was more than doubled in size, priced at $17 and never traded below $28.
Let's take a deep dive into sectors, the Fed and trade wars.
Omecamtiv mecarbil, a cardiac myosin activator, is being studied in heart failure with reduced ejection fraction (HFrEF)
Developing T cell engagers targeting prostate cancer, ovarian cancer, multiple myeloma and small cell lung cancer (Image: Harpoon Therapeutics)
The proposed deal for this biotechnology unicorn would be the largest US IPO in the industry (Image: Moderna)
The noise trader influence is only growing, as the rise of self-directed traders and the relentless noise of the financial press mean the noise to signal ratio is worse than ever.
| Last Price 242.21 | Change $ 1.89 | Change % 0.78 | Tick N/A |
| Bid 242.17 | Bid Size 100.00 | Ask 242.22 | Ask Size 100.00 |
| Open 239.51 | High 242.45 | Low 237.81 | Prev Close 240.32 |
| Last Trade | Volume 1.6 mi | 52 Wk Hi 264.98 | 52 Wk Low 177.06 |
| Market Cap 141.9 bi | Ex-Div Date | Div Rate 6.40 | Yield 2.6630 |
| Shares 585,693,775.00 | EPS (TTM) 12.26 | PE Ratio 19.60 | Exchange NGS |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 45 | 74 |
| Number of Buys | 23 | 31 |
| Number of Sells | 22 | 43 |
| Net Activity | -8304 | 75103 |
| Last 10 Buys | Shares |
|---|---|
| Fred Hassan | 1,000 |
| Fred Hassan | 1,000 |
| Frank C. Herringer | 1,000 |
| Frank C. Herringer | 1,000 |
| Robert A. Bradway | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Sean Harper | 1,000 |
| Sean Harper | 1,000 |
| Sean Harper | 1,000 |
| Sean Harper | 1,000 |
| Sean Harper | 1,000 |
| Sean Harper | 1,000 |
| Sean Harper | 1,000 |
| Sean Harper | 1,000 |
| De Francois Carbonnel | 1,000 |
| Sean Harper | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 224 | 224 | 224 | 224 |
| Low Target Price Estimate | 165 | 165 | 165 | 165 |
| Mean Target Price Estimate | 193.94 | 193.94 | 193.12 | 193.94 |
| Standard Deviation | 15.01 | 15.01 | 14.92 | 15.01 |
| Date of Most Recent Estimate | 06/03/18 | 05/22/18 | 05/22/18 | 06/03/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-12 |
| CT ORDER | 1 | 2018-05-30 | |
| 3 | Initial statement of beneficial ownership of securities | 1 | 2018-05-22 |
| 8-K | Report of unscheduled material events or corporate changes. | 8 | 2018-05-22 |
| CT ORDER | 1 | 2018-05-17 | |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-15 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-15 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-07 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-07 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-07 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 |
| Moderate Buy | 1 | 1 | 1 | 1 |
| Hold | 12 | 13 | 14 | 14 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 2.22 | 2.26 | 2.3 | 2.3 |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait